Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Mu

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2026
Correction: Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
World Journal of Gastroenterology|February 28, 2009
Genetic diagnosis strategy of hereditary non-polyposis colorectal cancerJian-Qiu Sheng, Hong Zhang, Min Ji, et al.
Journal for Immunotherapy of Cancer|December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatmentAmrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.
Leukemia|April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AMLYannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
The Journal of Clinical Investigation|March 5, 2019
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironmentSujan Piya, Hong Mu, Seemana Bhattacharya, et al.
Molecular Cancer Therapeutics|March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDSBing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control studyAntigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Blood|June 3, 2015
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapyByung-Sik Cho, Zhihong Zeng, Hong Mu, et al.
Translational Lung Cancer Research|December 10, 2025
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancerMary E Gwin, Mitchell S von Itzstein, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|May 14, 2026
Correction: Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
Metabolic syndrome and immune-related adverse eventsKatherine Lei, Meera J Patel, Jialiang Liu, et al.
World Journal of Gastroenterology|February 28, 2009
Genetic diagnosis strategy of hereditary non-polyposis colorectal cancerJian-Qiu Sheng, Hong Zhang, Min Ji, et al.
Journal for Immunotherapy of Cancer|December 9, 2021
Humoral and cellular correlates of a novel immune-related adverse event and its treatmentAmrit S Gonugunta, Mitchell S von Itzstein, Hong Mu-Mosley, et al.
Leukemia|April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AMLYannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
The Journal of Clinical Investigation|March 5, 2019
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironmentSujan Piya, Hong Mu, Seemana Bhattacharya, et al.
Molecular Cancer Therapeutics|March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDSBing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2022
Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control studyAntigona Ulndreaj, Davor Brinc, Mehmet Altan, et al.
Pageof 21